BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-73@catalystbrief.girapphe.com
DTSTAMP:20261117T061554Z
LAST-MODIFIED:20261117T061554Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Sound Pharmaceuticals\, Incorporated — Ebselen [Dec 2026
 ]
DESCRIPTION:Phase 3 primary completion: SPI-1005 for the Treatment of Menie
 re's Disease (Open Label).\nSource: https://clinicaltrials.gov/study/NCT06
 859788\nhttps://catalystbrief.girapphe.com/e/73?lang=en\nNot investment ad
 vice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/73?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
